The Lantern Pharma IPO Raises Some Questions

April 23. 2020. 6 mins read

We recently published a report on seven AI healthcare stocks noting that six were the result of recent IPOs. Of those, two are involved in drug discovery. We’ve written extensively about how machine learning and computational chemistry are speeding up the drug development process and decreasing the likelihood that drugs will fail. It’s all about taking an incredibly large amount of big data and turning it into insights. Today, we’re going to talk about another company that uses AI for drug discovery and just filed for an IPO – Lantern Pharma.

About Lantern Pharma

Founded in 2013, Texan startup Lantern Pharma has taken in $5.5 million in funding. The company’s platform, RADR, promises to find drugs that failed in other efforts and find new ways to apply them. After identifying late-stage drugs with a suitable history of safety and tolerability, the company uses loads of big data to then find the optimal subset of patients to conduct trials on.

Credit: Lantern Pharma

They then partner or license the drugs to pursue commercialization. The idea sounds great on paper, but it all comes down to execution.

The Devil is in the Deta

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.